Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

Abstract

In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year.

Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure

“…Many patients experienced both virological and immunological responses to HAART in terms of reduced levels of plasma HIV-1 RNA as well as increased levels of CD4 + T-lymphocytes [2,30]. Between 7% and 15% of HAART adult patients, however, have a seemingly paradoxical response to HAART in that their CD4 + lymphocytes levels increase substantially but their levels of plasma HIV-1 RNA remain high [ outcome than virological non-responders, the probability of clinical progression is low even in the latter group [33].…”

Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States

“…For several years, early treatment with antiretroviral therapy [59][60][61] and prophylaxis against P. carinii pneumonia [62] have been known to prolong survival and the time until AIDS-defining illnesses develop. The clinical picture and subsequent survival of persons with HIV infection [56,[63][64][65] have improved even more in recent years with combination therapy using two, three, or more antiretrovirals (including other nucleoside analog reverse-transcriptase inhibitors (RTIs) [65], protease inhibitors [66,67], and non-nucleoside RTIs [68]) that inhibit the constitutive enzymes of HIV and slow or prevent replication of HIV in vivo [39,69,70].…”

HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir–ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed

“…C ombination antiretroviral therapy for HIV-1 infection has resulted in profound control of HIV replication in vivo, improved immune function, and significant decreases in AIDS-related morbidity and mortality (1)(2)(3)(4)(5)(6)(7)(8)(9). For many persons, however, this therapy does not provide sustained viral suppression or durable clinical benefit (10,11).…”